---
schema_version: "secwatch.filing_event.v1"
accession: "0000926326-26-000019"
form_type: "8-K"
ticker: "OMCL"
cik: "0000926326"
company_name: "OMNICELL, INC."
filed_at: "2026-07-30T10:34:15+00:00"
generated_at: "2026-07-30T10:35:04.885478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Omnicell Q2 revenue $312M (+7% YoY); raises FY non-GAAP EPS and EBITDA guidance

## Summary
- GAAP net income $24M ($0.52 diluted EPS) vs $6M ($0.12) YoY; non-GAAP EPS $0.94 vs $0.45.
- Non-GAAP EBITDA $67M vs $38M YoY; received $15M in IEEPA tariff refunds.
- FY2026 guidance raised: non-GAAP EBITDA $175M-$185M, non-GAAP EPS $2.15-$2.30.
- Nnamdi Njoku promoted to President and COO effective July 1, 2026.
- Added Rick Couldry as SVP Chief Pharmacy & Clinical Officer and Dan Mandoli as SVP/GM Specialty Pharmacy.

## SEC filing metadata
- accession: 0000926326-26-000019
- form_type: 8-K
- ticker: OMCL
- cik: 0000926326
- company_name: OMNICELL, INC.
- filed_at: 2026-07-30T10:34:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926326/000092632626000019/0000926326-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926326/000092632626000019/omcl-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926326-26-000019
- JSON: https://secwatch.observer/filing/0000926326-26-000019.json
- Plain text: https://secwatch.observer/filing/0000926326-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.